Last updated on April 23, 2014 at 13:57 EDT

Latest Servier Group Stories

2013-09-24 04:22:06

LONDON, September 24, 2013 /PRNewswire/ -- Pascal Touchon, Head of Business Development and Scientific Cooperation, announced Servier Group's voluntary public offer for all outstanding shares of a majority-owned company, Egis, at a price of 28,000 HUF per share. Touchon added that Egis is their only affiliate to be listed on a stock exchange (BUX), and since the business does not require equity financing, "It makes little financial sense for Egis to maintain its presence on...

2012-09-20 02:28:20

ROCKVILLE, Md. and SURESNES, France, Sept. 20, 2012 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART(TM)) products directed at three undisclosed tumor targets. MacroGenics' DART...